Skip to main content
Erschienen in: Breast Cancer 1/2016

01.01.2016 | Original Article

Assessment of the Ki67 labeling index: a Japanese validation ring study

verfasst von: Naoki Niikura, Takashi Sakatani, Nobuyuki Arima, Yasuyo Ohi, Naoko Honma, Naoki Kanomata, Kazuya Yoshida, Takayuki Kadoya, Kentaro Tamaki, Nobue Kumaki, Takayuki Iwamoto, Tomoharu Sugie, Takuya Moriya

Erschienen in: Breast Cancer | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

A lack of consistent methods to evaluate Ki67 expression is problematic in terms of accurately predicting prognosis in breast cancer. Accordingly, this study aimed to identify the causes of discrepancies in Ki67 labeling index measurements by different observers under different conditions using breast cancer samples.

Patients and methods

This Japanese study group compared and assessed immunohistochemical (IHC) analysis of the Ki67 labeling index when measured by different pathologists. Six pathologists (pathologists A–F) in Japan participated in this ring study. One hundred and ten surgical cases of estrogen receptor-positive and human epidermal growth factor receptor 2-negative invasive breast cancer treated in 2007 were identified from the breast cancer database of Tokai University Hospital and were included in this study.

Results

For all 6 pathologists, the Ki67 labeling index were significantly different between grade 3 and grade 1 cases and between grade 3 and grade 2 cases, whereas the index tended to be different between grade 1 and grade 2 cases. Further, the Ki67 labeling indexes measured by the 6 pathologists were strongly correlated (ρ: 0.73–0.88). The IHC scores recorded by pathologist A were in moderate to good agreement with those recorded by the others in patients with a Ki67 labeling index of <13.25 % and in those with a Ki67 labeling index of >13.25 % (κ = 0.429–0.660). The Ki67 low and high concordance rates between pathologist A and the others were 0.452–0.778 and 0.862–0.979, respectively. The most pertinent reason for discrepancy in scores seemed to be the selection of the area for counting and the quality of nuclear staining.

Conclusion

The Ki67 labeling index measured by 6 pathologists without method standardization was in fair to good agreement. We plan to undertake a second ring study, pending recommendations by the international Ki67 panel.
Literatur
1.
Zurück zum Zitat Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013;142(1):69–80. Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013;142(1):69–80.
2.
Zurück zum Zitat Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.PubMedPubMedCentralCrossRef Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Niikura N, Iwamoto T, Masuda S, Kumaki N, Xiaoyan T, Shirane M, et al. Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci. 2012;103:1508–12.PubMedCrossRef Niikura N, Iwamoto T, Masuda S, Kumaki N, Xiaoyan T, Shirane M, et al. Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci. 2012;103:1508–12.PubMedCrossRef
4.
Zurück zum Zitat Urruticoechea A. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212–20.PubMedCrossRef Urruticoechea A. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212–20.PubMedCrossRef
5.
Zurück zum Zitat de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients. Br J Cancer. 2007;96:1504–13.PubMedPubMedCentralCrossRef de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients. Br J Cancer. 2007;96:1504–13.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health Recurrence Score in early breast cancer. J Clin Oncol. 2011;29(32):4273–8. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health Recurrence Score in early breast cancer. J Clin Oncol. 2011;29(32):4273–8.
7.
Zurück zum Zitat Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.PubMedPubMedCentralCrossRef Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Hugh J, Hanson J, Cheang MCU, Nielsen TO, Perou CM, Dumontet C, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27:1168–76.PubMedPubMedCentralCrossRef Hugh J, Hanson J, Cheang MCU, Nielsen TO, Perou CM, Dumontet C, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27:1168–76.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat von Minckwitz G, Schmitt WD, Loibl S, Muller BM, Blohmer JU, Sinn BV, et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2013;19:4521–31.CrossRef von Minckwitz G, Schmitt WD, Loibl S, Muller BM, Blohmer JU, Sinn BV, et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2013;19:4521–31.CrossRef
10.
Zurück zum Zitat Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206–23. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206–23.
11.
Zurück zum Zitat Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. JNCI J Natl Cancer Inst. 2011;103(22):1656–64. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. JNCI J Natl Cancer Inst. 2011;103(22):1656–64.
12.
Zurück zum Zitat Jonat W, Arnold N. Is the Ki-67 labelling index ready for clinical use? Ann Oncol. 2011;22:500–2.PubMedCrossRef Jonat W, Arnold N. Is the Ki-67 labelling index ready for clinical use? Ann Oncol. 2011;22:500–2.PubMedCrossRef
13.
Zurück zum Zitat Barton S, Zabaglo L, A’Hern R, Turner N, Ferguson T, O’Neill S, et al. Assessment of the contribution of the IHC4 + C score to decision making in clinical practice in early breast cancer. Br J Cancer. 2012;106:1760–5.PubMedPubMedCentralCrossRef Barton S, Zabaglo L, A’Hern R, Turner N, Ferguson T, O’Neill S, et al. Assessment of the contribution of the IHC4 + C score to decision making in clinical practice in early breast cancer. Br J Cancer. 2012;106:1760–5.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T. The efficacy and limitations of repeated slide conferences for improving interobserver agreement when judging nuclear atypia of breast cancer. The Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. Jpn J Clin Oncol. 1999;29:68–73.PubMedCrossRef Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T. The efficacy and limitations of repeated slide conferences for improving interobserver agreement when judging nuclear atypia of breast cancer. The Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. Jpn J Clin Oncol. 1999;29:68–73.PubMedCrossRef
15.
Zurück zum Zitat Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A’Hern R, et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res: BCR. 2010;12:R76.PubMedPubMedCentralCrossRef Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A’Hern R, et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res: BCR. 2010;12:R76.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Benini E, Rao S, Daidone MG, Pilotti S, Silvestrini R. Immunoreactivity to MIB-1 in breast cancer: methodological assessment and comparison with other proliferation indices. Cell Prolif. 1997;30:107–15.PubMedCrossRef Benini E, Rao S, Daidone MG, Pilotti S, Silvestrini R. Immunoreactivity to MIB-1 in breast cancer: methodological assessment and comparison with other proliferation indices. Cell Prolif. 1997;30:107–15.PubMedCrossRef
17.
Zurück zum Zitat Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol. 2002;198:292–9.PubMedCrossRef Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol. 2002;198:292–9.PubMedCrossRef
18.
Zurück zum Zitat Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer Sci. 2013;104(11):1539–43. Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer Sci. 2013;104(11):1539–43.
19.
Zurück zum Zitat Denkert C, Loibl S, Muller BM, Eidtmann H, Schmitt WD, Eiermann W, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2013;24(11):2786–93. Denkert C, Loibl S, Muller BM, Eidtmann H, Schmitt WD, Eiermann W, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2013;24(11):2786–93.
20.
Zurück zum Zitat Hida AI, Oshiro Y, Inoue H, Kawaguchi H, Yamashita N, Moriya T. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells. Breast Cancer. 2013. doi:10.1007/s12282-013-0460-8. Hida AI, Oshiro Y, Inoue H, Kawaguchi H, Yamashita N, Moriya T. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells. Breast Cancer. 2013. doi:10.​1007/​s12282-013-0460-8.
21.
Zurück zum Zitat Tamaki K, Ishida T, Tamaki N, Kamada Y, Uehara K, Miyashita M, et al. Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients. Breast Cancer. 2012;21(3):325–33. Tamaki K, Ishida T, Tamaki N, Kamada Y, Uehara K, Miyashita M, et al. Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients. Breast Cancer. 2012;21(3):325–33.
22.
Zurück zum Zitat Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. JNCI J Natl Cancer Inst. 2008;100:207–12.PubMedCrossRef Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. JNCI J Natl Cancer Inst. 2008;100:207–12.PubMedCrossRef
23.
Zurück zum Zitat Williams DJ, Cohen C, Darrow M, Page AJ, Chastain B, Adams AL. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. Appl Immunohistochem Mol Morphol. 2011;19:431–6.PubMedCrossRef Williams DJ, Cohen C, Darrow M, Page AJ, Chastain B, Adams AL. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. Appl Immunohistochem Mol Morphol. 2011;19:431–6.PubMedCrossRef
Metadaten
Titel
Assessment of the Ki67 labeling index: a Japanese validation ring study
verfasst von
Naoki Niikura
Takashi Sakatani
Nobuyuki Arima
Yasuyo Ohi
Naoko Honma
Naoki Kanomata
Kazuya Yoshida
Takayuki Kadoya
Kentaro Tamaki
Nobue Kumaki
Takayuki Iwamoto
Tomoharu Sugie
Takuya Moriya
Publikationsdatum
01.01.2016
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 1/2016
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-014-0536-0

Weitere Artikel der Ausgabe 1/2016

Breast Cancer 1/2016 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.